Second registration trial of tenapanor to treat hyperphosphatemia

Trial Profile

Second registration trial of tenapanor to treat hyperphosphatemia

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Hyperphosphataemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Ardelyx
  • Most Recent Events

    • 21 Nov 2017 According to an Ardelyx media release, based on the feedback recently received, the company will add an active control arm to the study for safety assessment only, consistent with the design of registration studies for phosphate binders. Ardelyx is updating the study protocol and preparing to begin enrollment.
    • 09 Aug 2017 According to an Ardelyx media release, the company expects to begin patient enrollment by October of 2017.
    • 17 Feb 2017 According to an Ardelyx media release, company is planning to initiate this trial by mid-year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top